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Abstract: Thiopeptides, or thiazolyl peptides, are a relatively new family of antibiotics that 
already counts with more than one hundred different entities. Although they are mainly 
isolated from soil bacteria, during the last decade, new members have been isolated from 
marine samples. Far from being limited to their innate antibacterial activity, thiopeptides 
have been found to possess a wide range of biological properties, including anticancer, 
antiplasmodial, immunosuppressive, etc. In spite of their ribosomal origin, these highly 
posttranslationally processed peptides have posed a fascinating synthetic challenge, 
prompting the development of various methodologies and strategies. Regardless of their 
limited solubility, intensive investigations are bringing thiopeptide derivatives closer to the 
clinic, where they are likely to show their veritable therapeutic potential. 
Keywords: thiopeptides; antibiotics; natural products; peptides; heterocycles; thiazole; 
oxazole; dehydroamino acids; pyridine 
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1. Introduction 
Since the discovery of the first antibiotics and their golden age in mid 20th century, there has been a 
dramatic change in the way we face the development of new antimicrobials [1,2]. At first, it seemed 
that the many classes of naturally occurring antibiotics could be sufficient to fight against bacterial 
infections, whereas, for the last few decades it was thought that semi-synthetic modifications of those 
natural products would be enough to overcome pathogen resistance. However, we are now facing a 
new age, where the discovery of novel scaffolds and new modes of action is required to fight against 
the emergence of resistances and cross-resistances that make previously treatable infections a  
new threat. 
Most of the antibacterial scaffolds known to date were discovered from late 1930s to early 1960s. 
After that period, almost forty years followed without new bactericide architectures appearing in the 
market. During those years, semi-synthetic modifications of the already known compounds were used 
to fight antibacterial resistance. However, with the new century, a batch of new antibiotic scaffolds got 
closer to the clinic (Figure 1). These include oxazolidinones (linezolid, 2000), lipopeptides 
(daptomycin, 2003) and mutilins (retapamulin, 2007). In parallel, other types of antibiotics, such as 
lantibiotics [3] (NVB302) and thiopeptides [4] (LFF571) [5], are under study and some members of 
these groups are already in clinical trials for the treatment of human infections. 
Figure 1. Members of new classes of antibiotics. Abu = aminobutyric acid. 
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Among these new families of antibiotics, thiopeptides have gathered much attention due to their 
potent in vitro activity against Gram-positive bacteria and their intriguing structures. During the last 
two decades, intensive investigations on known thiopeptides, their semisynthetic modification and the 
discovery of new members of this class of antibiotics have been the focus of the efforts of many 
research groups. 
2. Thiopeptides 
Thiopeptides, or thiazolyl peptides [4], are highly modified sulfur-rich peptides of ribosomal origin. 
They all share a series of common motifs that differentiate them from other peptide-derived and/or 
azole-containing natural products. Their most characteristic feature is the central nitrogen-containing 
six-membered ring, which can be found in many different oxidation states. This central ring serves as 
scaffold to at least one macrocycle and a tail, and both can be decorated with various dehydroamino 
acids and azoles, such as thiazoles, oxazoles, and thiazolines. All these moieties are formed though 
dehydration/dehydrosulfanylation of Ser, Thr, and Cys residues. Their impressive in vitro profile 
against Gram-positive bacteria, and their new mechanisms of action, have gathered the attention of 
many groups, both in academia and industry, as they pose an alternative to other antibiotics presently 
facing resistance by old pathogens. To date, more than one hundred members of this family of natural 
products have been identified; however, their very large molecular size and their poor aqueous 
solubility have been a major drawback to introduce them into the clinic. This has become their major 
limitation and has restricted their use to topic treatments, and so far only for pet skin infections 
(thiostrepton, Panolog). 
Given the different oxidation state the central ring of thiopeptides can be found in, they have been 
classified into different series (Figure 2) [4]. Thus, the a series presents a totally reduced central 
piperidine, whereas the b series is oxidized further and contains a 1,2-dehydropiperidine ring. Only one 
thiopeptide of the c series has been isolated to date and its core moiety is somewhat unexpected, as it 
displays a piperidine ring fused with imidazoline. All members of series a, b, and c have a second 
macrocycle, which contains a quinaldic acid moiety. The d series goes further on the oxidation state 
rank and shows a trisubstituted pyridine ring, which is the landmark of this subgroup, the most 
numerous among thiopeptides. In a sense, the e series is even more oxidized and is easily differentiated 
for the hydroxyl group in the central pyridine, which is now tetrasubstituted. The e series also presents 
a very characteristic second macrocycle appending from the main one and formed by a modified  
3,4-dimethylindolic acid moiety. 
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Figure 2. Classification of thiopeptide antibiotics into different series. Their characteristic 
central six-member ring is highlighted in bold. 
 
2.1. Isolation and Structure Elucidation 
Thiopeptides have been isolated from diverse sources. In 1948, the first known member of the 
family, micrococcin [6], was isolated from a sample of Oxford’s sewage waters. Accounting for the 
highly diverse origin of thiopeptides, micrococcin P1 was more recently isolated from a completely 
different source, a French cheese [7]. However, more conventional samples, such as from soil are the 
main source of most thiopeptides. In fact, thiostrepton, the most famous member of the family, has 
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been isolated from different soil samples [8–10], including one from Hawaii in 1955 [11], shortly after 
it was first discovered in 1954 [8–10]. Although a few more thiopeptides were isolated during the 
following years, it was from the 1980s, especially during the 1990s, that most of the known members 
were discovered. Nonetheless, many novel entities have also been described during the last decade. 
Remarkably, the first thiopeptide antibiotics isolated from a marine source were YM-266183 and  
YM-266184, discovered as late as 2003, in Japan [12]. During the last few years some more 
thiopeptides have been isolated and characterized; these include the thiazomycins (2007) [13–16], 
philipimycin (2008) [17], thiomuracins (2009) [18], TP-1161 (2010) [19,20], baringolin (2012) [21], 
and kocurin (2013) [22] (Figure 3). 
Figure 3. Some of the most recently described thiopeptides. 
 
The assignment of thiopeptide structures can be a very complex task, as exemplified by 
thiostrepton, of which structure elucidation was originally addressed by degradation studies and 
structure determination of fragments [23]. However, the later use of X-ray diffraction was essential to 
elucidate both connectivity and stereochemistry [24,25]. Although the development of NMR 
spectroscopy techniques has permitted the elucidation of many structures of thiopeptides, a high 
degree of uncertainty remains until further evidence is provided. This was clearly the case of 
micrococcin P1 [26]. Early studies on its constitution by hydrolysis [27–29] of the natural extract 
permitted the identification of most moieties present in micrococcin; however, there was no clear 
evidence of its connectivity. Later on, NMR studies [30–32] and synthesis of proposed  
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structures [33–36] of the natural compound resulted in better hypotheses for its constitution and 
stereochemistry, although none of the synthesized products was identical to the natural one. It was not 
until its total synthesis was achieved by Ciufolini in 2009, 51 years after its discovery, that 
micrococcin P1 structure and stereochemistry were finally confirmed [37]. 
The structure of most thiopeptides has been investigated by a combination of degradation, mass 
spectrometry and NMR studies. The impossibility to obtain crystals for the vast majority of them 
prompted the assignment of their structure without a clear evidence of their stereochemistry. In spite of 
this limitation, in many cases their configuration has been proposed by analogy with similar  
isolates [38,39], via amino acid analysis [40–42] or via isotopic labeling through feeding with labeled 
amino acids [43,44]. In some cases, less conventional techniques have been chosen. Such are the cases 
of promoinducin and thiotipin, where chiral TLC was used to determine the configuration of L-Thr 
from an acidic hydrolysate [45,46]. Absolute configurations have also been reported after NMR 
spectroscopy studies and chiral capillary electrophoresis [47]. 
As exemplified by micrococcin P1, a synthetic approach to the problem can serve as the ultimate 
confirmation for both connectivity and stereochemistry. This strategy also includes the comparison of 
fragments with their synthetic counterparts; such was the case of GE2270A [48]. Synthesis of 
thiopeptides polyheterocyclic cores has been used to confirm the structure of the corresponding 
degradation products, while, at the same time, it has also permitted the development of the necessary 
synthetic methodology [49]. 
2.2. Biosynthesis 
The biosynthetic pathway of thiopeptides has been very elusive for a long time; however, recent 
discoveries have put light on the synthesis of these highly modified peptides. Peptide-based natural 
products can have two distinct origins depending on how their amino acids are condensed together to 
form the parent peptides. These can be either synthesized on the ribosome as product of mRNA 
translation or can be assembled by nonribosomal peptide synthases (NRPSs). Though most highly 
modified peptide-derived natural products are synthesized by NRPSs, there was no evidence of such 
origin for thiopeptides. Surprisingly, very recent discoveries by four different groups have 
demonstrated that parent pre-peptide of thiopeptide is ribosomally synthesized and, thus, is genetically 
encoded [19,50–52]. 
Joint efforts of bio-informatics and genome mining have been essential for the identification of 
genes that encode the precursor peptide and the enzymatic machinery necessary for its subsequent 
tailoring [18,20,50–59]. The gene encoding the precursor peptide has been identified for many 
thiopeptides and, in all cases, there is a perfect agreement with the expected amino acid sequence. This 
precursor peptide is divided in two different regions, a structural peptide of 12 to 17 residues at the  
C-terminus, which contains the amino acids that will constitute the thiopeptide itself, and a leading 
peptide of 34 to 55 residues at the N-terminus, which is cleaved during the bio-synthetic process. In 
some cases, the C-terminal structural peptide contains one or two extra residues that are cleaved during 
the tailoring to confer each thiopeptide its characteristic C-terminus [60,61]. All necessary enzymes for 
pre-peptide tailoring are encoded in genes surrounding that of the precursor peptide, forming a gene 
cluster (see Figure 4 for an example on thiomuracins’ gene cluster (tdp) and precursor peptide [18]; in 
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the gene cluster, genes appear as arrows and are named with letters. Each gene (tdpX) codes a gene 
product, a protein/enzyme (TdpX)). 
Figure 4. The biosynthetic gene cluster of tiomuracins and their precursor peptide 
sequence, which is coded in the structural gene. In the precursor peptide sequence, the 
structural peptide is numbered with positive figures and the leading peptide with negative 
ones. Residues that appear in the mature thiopeptide are underlined. 
 
The role of most enzymes present in some thiopeptides gene clusters has been already discovered. 
Similarity with known enzymes of the same function, gene deletions, and characterization of products 
that result from transformations with isolated enzymes, have permitted to establish which 
transformations and in which order they take place [51,58,59,62–68]. Apparently, oxazole, thiazole, 
and thiazoline rings are formed first through cyclization, dehydration, and, if required, oxidation of 
Ser, Thr, and Cys residues. In a second step, Ser and Thr phosphorylation and elimination yields the 
corresponding dehydroalanine (Dha) and dehydrobutyrine (Dhb) residues, respectively. Finally, 
intramolecular aza-Diels-Alder-like cycloaddition between distant Dha residues occurs, followed by 
dehydration, and, when required, elimination to constitute the central six-membered ring. Further  
side-chain modifications, such as oxidations, cyclizations, methylations, and incorporation of indolic 
or quinaldic acid moieties seem to occur in later stages of the bio-synthetic pathway (see Scheme 1 for 
an example on thiomuracin I biosynthesis [18]). 
Scheme 1. Biosynthetic pathway of thiomuracin I. LP = leading peptide. Enzymes 
involved in the biosynthetic pathway (TdpX) are named according to their corresponding 
gene (tdpX) in thiomuracins’ gene cluster (tdp). 
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Both quinaldic and indolic acid moieties found in a–c and e series thiopeptides are synthesized from 
L-Trp and are part of the second macrocycle found in these compounds. This was first demonstrated by 
labeling [69–72] and enzyme function [73,74] experiments and, more recently, also using genetic 
engineering methods [63,65–67]. 
In the case of indolic acid formation, Trp undergoes a radical-mediated rearrangement and Cα 
migrates to position 2 of indole (Scheme 2). Subsequently, S-adenosylmethionine-dependent  
4-methylation of the aromatic scaffold after condensation with the structural peptide yields an 
advanced intermediate of the mature thiopeptide [65,75]. 
Scheme 2. Biosynthesis of indolic acid moietiy from Trp and incorporation into 
nosiheptide. Enzymes involved in the biosynthetic pathway (NosX) are named according to 
their corresponding gene (nosX) in gene cluster of nosiheptide (nos). 
 
Alternatively, quinaldic acid synthesis starts with S-adenosylmethionine-mediated methylation of 
Trp (Scheme 3) [52,66]. Deamination/oxidation steps follow and after ring opening, recyclization 
yields the quinaldic acid moiety. This is then reduced, attached to the structural peptide, and 
epoxidized. Upon epoxide opening, the second macrocycle of thiostrepton is formed. 
Scheme 3. Biosynthesis of quinaldic acid moietiy from Trp and incorporation  
into thiostrepton. 
 
C-terminal tailoring is one of the last steps in thiopeptides maturation. In those cases where a  
C-terminal amide is present, two distinct mechanisms have been described for its formation  
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(Scheme 4). Nosiheptide structural peptide contains an extra C-terminal Ser residue, which is lost 
during tail maturation, giving rise to a C-terminal amide [60]. By contrast, structural peptide of 
thiostrepton does not contain any extra amino acids and its C-terminal Ser residue can be methylated to 
form the corresponding ester (Scheme 4). The C-terminal amide is formed by deesterification and 
subsequent amidation using Gln as nitrogen donor [61].
 
Scheme 4. Proposed mechanisms for C-terminal amide formation during nosiheptide and 
thiostrepton maturation. 
 
2.3. Biological Activity 
Thiopeptides are best regarded as antibacterial agents, however, their therapeutic potential is 
surprisingly broad and have been found to posses anticancer [76–82], antiplasmodial [83–88], 
immunosuppressive [89], renin inhibitory [90], RNA polymerase inhibitory [91], and antifungal [92] 
activities. This wide variety of biological functions has resulted in a very prolific literature outcome, 
positioning the macrocyclic scaffold of thiopeptides as a veritable privileged structure. 
2.3.1. Antibacterial Activity 
It is already well established that thiopeptides exert their antibacterial function via the inhibition of 
ribosomal protein synthesis. However, this is the result of different mechanisms of action that depend 
on macrocycle size. Thiopeptides exhibit macrocycles of three different sizes, 26-, 29-, and  
35-membered rings, depending on the number of residues present. On one hand, thiopeptides of  
26-member macrocycles, such as that of micrococcin P1 and the siomycins (Figure 5), are known to 
bind the GTPase-associated region of the ribosome/L11 protein complex. By doing so, the thiopeptide 
blocks the binding region of elongation factor G (EF-G) and does not allow translocation of the 
growing-peptide/tRNA complex in the ribosome to occur [93–95]. On the other hand, those 
thiopeptides with a 29-membered ring, in the fashion of GE37468A, bind to elongation factor Tu  
(EF-Tu), blocking its tRNA/amino acyl complex binding site [96–98]. As a consequence, the complex 
cannot be delivered into the ribosome and peptide elongation does not take place. Compounds with the 
largest macrocycles, those with 35-membered rings, maintain potent antibacterial activity; however, 
their molecular target still remains unknown. 
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Figure 5. Thiopeptides have macrocycles of different sizes that determine their mode  
of action. 
 
Somewhat related to antibacterial activity is tipA gene promotion, which encodes two  
thiostrepton-induced proteins (Tip), TipAL and TipAS [99]. The latter, TipAS, serves as a mechanism 
of defense for bacteria, as it sequesters and covalently binds a thiopeptide molecule, which can no 
longer inhibit ribosomal protein synthesis. TipA promotion has been used to identify thiopeptides in a  
high-throughput screening program, which detected transcription of the promoter of tipA (ptipA) and 
led to the discovery of geninthiocin [100] (Figure 6). Other thiopeptides, such as thiotipin [46] and 
thioxamycin [42], and promothiocins [101] were also discovered thanks to their tipA promoting 
activity. Interestingly, the 35-membered thiopeptide radamycin is completely devoid of antibacterial 
activity, but is a very strong inducer of tipA gene expression (Figure 6). Various tipA promoting 
thiopeptides are depicted in Figure 6, where very preserved regions, associated with key interactions 
for binding with ribosome/L11 complex [102], are highlighted. Although those residues are different in 
radamycin, promothiocin B displays those same, not-preserved residues in a smaller 26-membered 
macrocycle and retains potent antibacterial activity. Apparently, tipA promotion activity is more 
dependent on the presence of a dehydroalanine-containing tail close to the six-membered central 
scaffold [103]. 
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Figure 6. Thiopeptides with tipA promoting activity. A very preserved region, which has 
been shown to interact with the ribosome/L11 complex, is highlighted (solid squares). 
Radamycin, devoid of antibacterial activity, has a mutated sequence in the previously 
mentioned region (hashed squares). Promothiocin B possesses the same mutated residues, 
but maintains antibacterial activity, though in a 26-membered macrocycle. 
 
Thiopeptides known or presumed to bind to EF-Tu, those with 29-membered macrocycles, also 
possess a very preserved residue in their macrocycle, pointing to a key interaction required to exert 
their biological activity. The amythiamicins, baringolin, the GE2270 series, GE37468 A, and the 
thiomuracins, all belonging to the d series, preserve an Asn residue in the same position that is either 
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methylated or not (Figure 7). Codon randomization experiments by Walsh et al. [104] produced 
various GE37468 A analogs that substituted Asn with Ala, Cys, His, and Ser; however, none of these 
analogs retained antibacterial activity, supporting the key role of this residue. Apart from providing a 
key contact with EF-Tu, the Asn residue participates in the stabilization of the bioactive conformation 
of the macrocycle, providing a transannular H-bond [105]. 
Figure 7. 29-membered thiopeptides with a very preserved Asn residue highlighted with  
a square. 
 
2.3.2. Other Activities 
One of the biological properties of thiopeptides of major interest, apart from the antibacterial one, is 
anticancer activity. In this regard, thiostrepton was found to selectively kill cancer cells without 
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showing any cytotoxicity against healthy tissues [106]. Such a promising effect has been demonstrated 
to arise from selective inhibition of transcription factor forkhead box M1 (FOXM1) [78,81,82]. 
FOXM1 overexpression is associated with the development and progression of cancer and its selective 
targeting is a very large achievement, as transcription factors have been considered undruggable for a 
long time [107,108]. 
During synthetic efforts of Nicolaou’s group, it was discovered that the central core of  
thiostrepton (1) retained some antibacterial, but an increased potency against all cancer cell lines tested 
(Table 1) [76]. 
Table 1. Thiostrepton fragment 1 outperforms its parent compound against various cancer 
cell lines. 
 
Compound 
LC50 (μM) IC50 (μM) 
NCI-H460 HCT-116 SK-OV-3 MCF-7 K-562 1A9 PTX10 A8 AD10 
thiostrepton 1.5 1.6 2.8 3.8 1.7 0.96 1.1 0.9 91.0 
1 0.9 0.6 1.2 0.9 0.8 0.07 0.1 0.2 0.4 
Many thiopeptides have been found to possess anti-malaria activity [83–87]. Although Plasmodium 
falciparum parasite cell is eukaryote, thiopeptides target apicoplast protein synthesis [109], which 
resembles that of prokaryotic organisms. Although it has been demonstrated that thiostrepton binds to 
the apicoplast 23S rRNA [83], thiopeptides of the d series, such as micrococcin P1 and amythiamicin 
A, are much more potent inhibitors of P. falciparum growth [84]. 
Very recently, the use of thiostrepton semi-synthetic analogs has demonstrated that it targets both 
the apicoplast ribosomes and the proteasome of P. falciparum [88]. This dual mode of action could 
make thiostrepton and similar thiopeptides less prone to resistance development than single-target drugs. 
A screening program in search of immune-suppressants identified siomycin as inhibitor of antibody 
production by murine B-cells [89]. Comparison with thiostrepton showed the superior behavior of the 
structurally similar siomycin. Both thiopeptides are thought to possess a different mechanism of action 
than that of FK506, a common immunosuppressant drug, and would act directly on B-cells. 
Clyclothiazomycin is a very unique thiopeptide that does not possess a tail (Figure 8). In fact, the 
azole-containing branch that would serve as tail is linked to the macrocycle, forming a second ring, 
different from those found in thiopeptides of series a–c and e. However, due to its central  
tri-substituted pyridine ring, it is still considered a member of the d series. Perhaps due to its peculiar 
structure, different activities have been found for it. The first one to be described was human plasma 
renin inhibitory activity [90]. Renin is an enzyme associated with hypertension [110], diabetes [111], 
and Alzheimer’s disease [112] and is a rate-limiting enzyme in a cascade that starts with the cleavage 
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of angiotensiogen and ends with the formation of angiotensin II. Due to this, renin is regarded as one 
of the most effective targets to treat hypertension. 
Figure 8. Cyclothiazomycin and its more recently isolated analogs B1 and B2. 
 
Thiopeptides with a very similar structure to cyclothioazomycin were recently isolated and 
characterized and were named after the parent compound (Figure 8) [91]. In particular, 
cyclothiazomycin B1 was found to inhibit transcription by bacteriophage RNA polymerase. Such 
result might serve to further understand transcription at the molecular level. 
Cyclothiazomycin B1 (Figure 8) also exhibits antifungal activity and inhibits the growth of various 
filamentous fungi. It presumably does so by binding to chitin, causing cell wall fragility [92]. 
Saramycetin has also been described as an antifungal thiopeptide [113]; however, it was not fully 
characterized and might not fulfill the structural requirements to fall into this family of natural products. 
2.4. Conformation and Binding 
The structure of thiopeptides has been studied using different techniques, which have also been 
used to elucidate the active conformation and the key contacts required to exert their biological 
activity. Though thiopeptides are relatively large molecules with big macrocycles, they possess many 
azoles, dehydroamino acids and amide bonds that confer the required rigidity for efficient  
binding [114]. First conformational studies were performed by NMR and provided solution structures 
of the promothiocins [115], nocathiacin I [47] and amythiamicin D [105]. For amythiamicin D, an 
intramolecular H-bond was detected [105], which seems to favor the bioactive conformation. The same 
H-bond interaction can be observed between the equivalent positions of active GE2270A and 
thiomuracin A analogs [116,117]. NMR studies of the thiostrepton/L11/rRNA complex [102] 
identified key contacts in the 26-membered ring of thiostrepton that led to the design of small analogs 
that maintained their binding capability [118]. 
X-ray analysis of the L11/rRNA complex and superimposition with optimized thiopeptide 
structures have determined that compounds targeting this complex bind to a cleft between the 
ribosome and L11 protein [94,95,119]. This region, the so-called GTP associated center (GAC), is also 
the binding site of elongation factor G (EF-G), which is responsible for translocation during ribosomal 
protein synthesis. 
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Alternatively, mutation studies have been carried out to study the thiostrepton/L11/rRNA ternary 
complex. Site-directed mutation of L11 to introduce a Cys residue in a suitable surface position, 
permitted proximity induced covalent capture (PICC) experiments to be carried out (Figure 9) [93]. In 
a PICC experiment, the newly introduced Cys should perform a 1,4-conjugated addition to a Dha 
residue of the thiopeptide tail. These experiments suggested a slightly different binding mode for 
thiostrepton, which would not sit right inside the cleft between L11 and the 23S rRNA, but closer to 
the ribosome surface. Further mutation studies of either L11 or 23S rRNA were in agreement with this 
alternative binding mode, demonstrating that mutations on L11 did not avoid thiostrepton binding, 
whereas mutations on the ribosome diminished affinity between the complex and the thiopeptide [120]. 
Figure 9. Proximity induced covalent capture. Mutated L11 protein has an external Cys 
residue in the area where interaction with the tail of thiostrepton is expected.  
Tsr = thiostrepton. 
 
2.5. Chemical Synthesis 
The complex architectures and challenging structures of thiopeptides have gathered the attention of 
many groups that have envisioned different strategies to accomplish their syntheses [49]. Pioneering 
work by the groups of Kelly [121–124], Shin [35], Moody [125,126], Nicolaou [127,128],  
Ciufolini [36,37], and Bach [127,129,130] developed different methodologies that led to the total 
synthesis of various thiopeptides. However, most efforts have been devoted to the construction of the 
central polyheterocyclic core [121–124,131–138], which have been synthesized by two  
well-distinguished main strategies: modification of an existing pyridine and construction of the  
central ring. 
2.5.1. Modification of Pyridine 
Early efforts by Kelly’s group focused on the synthesis of different thiopeptide cores [121–124] 
(Scheme 5). One of his landmark achievements was the synthesis of dimethyl sulfomycinamate (2), a 
product of acidic methanolysis of sulfomycin [139]. Selective bromination of 3 provided pyridine 4, 
which contained three well-differentiated positions. Stille cross-coupling with 5, oxazole formation 
using acrylamide 6 and an in situ stannation/cross-coupling protocol with bromothiazole 7 permitted 
the installment of the two azole rings present in 2. 
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Scheme 5. Kelly’s synthesis of dimethyl sulfomycinamate. Reagents and conditions:  
(a) Br2, pyridine, rt, 77%; (b) MeI, K2CO3, acetone, reflux, overnight 88%; (c) KMnO4,  
90 °C, 3 h; (d) ClCO2Me, Et3N, DMAP, CH2Cl2, 0 °C to rt, 2 h, 65%; (e) AlCl3, CH2Cl2, 
reflux, 2 days, 93%; (f) Tf2O, 2,6-lutidine, CH2Cl2, 0 °C, 5 min, 95%; (g) 5, PdCl2(PPh3)2, 
1,4-dioxane, 100 °C, overnight 97%; (h) NBS, THF, H2O, rt, 10 min, 95%; (i) 6, THF 
sealed tube, 100 °C, 3 days, 65%; (j) OsO4, NaIO4, 1,4-dioxane, H2O, rt 3 h, 85%;  
(k) 7, Sn2Bu6, PdCl2(PPh3)2, Pd(PPh3)4, LiCl, 1,4-dioxane, 100 °C, overnight, 35%. 
 
Shin and co-workers developed their own strategies and synthesized many polyheterocyclic cores 
and fragments, such as GE2270 A central core (8) [140–147]. Most of their syntheses start from a  
pre-functionalized pyridine or pyridone of the like of 9 (Scheme 6). For the synthesis of 8, thiazoles 
were constructed using different methods, including Hantzsch syntheses with ethyl bromopyruvate and 
thioamide 10, followed by condensation of aldehyde 11 with Cys 12 and subsequent oxidation with 
activated manganese (II) oxide. 
Bach’s group described a very convergent approach to the enantiomer of GE2270 A core (13), 
which started from 2,3,6-tribromopyridine (14), and was fully based on sequential cross-coupling 
reactions with thiazoles 15−17 [135] (Scheme 7). This work served for confirmation of the 
polyheterocyclic core stereochemistry and also set the methodology for further syntheses of  
GE2270A [129] and amythiamicins A and D [148]. 
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Scheme 6. Shin’s synthesis of GE2270A central core. Reagents and conditions: (a) H2S, 
DMAP, Et3N, pyridine, rt, 3 days, 90%; (b) i. KHCO3, BrCH2COCO2Et, THF, 0 °C, then 
rt, overnight; ii. TFAA, pyridine, THF, 0 °C, 1 h, then rt, overnight, 53%; (c) Tf2O, 
DMAP, pyridine, 0 °C, 1 h, then rt, overnight, 93%; (d) ethyl vinyl ether, Et3N, dppp, 
Pd(OAc)2, toluene, reflux, overnight, 73%; (e) NBS, THF, H2O, rt, 5 min; (f) i. 10, 
KHCO3, DME, 0 °C, 1 h, then rt, overnight; ii. TFAA, pyridine, 0 °C, 2 h, 63% (2 steps); 
(g) 2 M HCl in THF, rt, 24 h; (h) i. 12, Et3N, toluene, rt, 15 min; ii. MnO2, toluene, rt, 12 h, 
41% (2 steps). dppp = 1,3-bis(diphenylphosphino)propane; Pac = Phenacyl. 
 
Scheme 7. The synthesis of ent-GE2270A central core by Bach. Reagents and conditions: 
(a) BuLi, ZnCl2, THF; (b) 15, PdCl2(PPh3)2, THF, 81% (2 steps); (c) BnNH2, DiBAL-H, 
THF, CH2Cl2, 86%; (d) 16, PdCl2(PPh3)2, THF, DMA, 78%; (e) 17, Pd(PPh3)4,  
1,4-dioxane, 80 °C, 61%. 
 
More recently, the group of Hoarau optimized conditions for the cross-coupling of  
thiazole-4-carboxylates (18) with pyridines using direct C-H activation on thiazole position 2 [137] 
and also formation of pinacolboronic acid and in situ cross-coupling on thiazole position 4, which is 
limited to 2-acylthiazoles, such as 19 [138]. Using, both, cross-coupling methodologies and Hantzsch 
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thiazole synthesis with bromoketone 20, the synthesis of ethyl tert-butylmicrococcinate (21) was 
achieved [138] (Scheme 8). 
Scheme 8. Synthesis of ethyl tert-butylmicrococcinate using direct C-H activation and  
one-pot borylation/cross-coupling of thiazoles. Reagents and conditions: (a) 18, Pd(OAc)2, 
Cy-JohnPhos, Cs2CO3, DMF, 110 °C, 18 h, 74%; (b) CO(NH2)2, H2O2, TFAA, MeCN,  
0 °C, 30 min; (c) POCl3, toluene, DMF, rt, 6 h, 78% (2 steps); (d) NH4OH, THF, rt, 82%; 
(e) Lawesson’s reagent, toluene, 2 h, 76%; (f) 20, EtOH, THF (1:1), 65%; (g) i. 19, 
bispinacolatodiboron, Pd2(dba)2, Cy-JohnPhos, KOAc, dioxane, 110 °C, 30 min; ii. K3PO4, 
dioxane, H2O, 110 °C, 12 h, 87%. 
 
The last example of cross-coupling-based construction of thiopeptide polyheterocyclic cores was 
reported by Álvarez’s group [149] and used the regioselective differentiation of the two α positions in 
2,6-dichloronicotinic acid (22) [150]. This strategy gave access to baringolin’s central core (23), 
facilitating its total synthesis [151] (Scheme 9). The carboxylic acid present in 24 was used to 
construct oxazole 25 and subsequent Stille cross-coupling with 26 [152] provided methoxypyridine 27. 
After conversion of 27 to the corresponding triflate 28, Negishi cross-coupling with 29 yielded 23. 
2.5.2. Construction of the Central Ring 
One of the most appealing contributions and the first one to rely on construction of the pyridine ring 
was Ciufolini’s synthesis of micrococcin’s central polyheterocylic core (30) [131] (Scheme 10). With 
the required thiazole building blocks, 31 and 32, in hand, the pyridine ring is formed in two steps in 
almost quantitative yield. This led to the synthesis of the Bycroft-Gowland structure of micrococcin 
P1, which had been miss-assigned [36]. It took ten more years to finally synthesize the true structure of 
micrococcin P1 and confirm its stereochemistry [37]. Using the same strategy, thiocillin I has been 
recently synthesized [153]. 
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Scheme 9. Synthesis of baringolin’s central polyheterocyclic core. Reagents and 
conditions: (a) tBuOK, MeOH, 65 °C, 4 days, 85%; (b) H-Thr-OBn, pyBOP, DIPEA, 
THF, 0 °C, 3 h, 89%; (c) Dess-Martin periodinane, CH2Cl2, rt, 6 h, 95%; (d) PPh3, I2, NEt3, 
CH2Cl2, 0 °C to rt, 15 h, 78%; (e) 26, Pd(PPh3)4, 1,4-dioxane, 80 °C, 48 h, 88%; (f) HBr, 
AcOH, rt, 28 h, 73%; (g) (Boc)2O, NEt3, CH2Cl2, 0 °C, 4 h, 94%; (h) Tf2O, 2,6-lutidine, 
DMAP, CH2Cl2, 0 °C to rt, 3 h, 88%; (i) 29, Pd(PPh3)4, DMA, 45 °C, 1 h, quant. 
 
Scheme 10. The synthesis of the polyheterocyclic core of micrococcin P1 by Ciufolini. 
Reagents and conditions: (a) cat. Li2CO3, EtOAc, 92%; (b) NH4OAc, EtOH then DDQ, 
toluene, 97%. 
 
Bagley, first in Moody’s group, and co-workers also described their own syntheses of the 
thiopeptide cores, such as the amythiamicins core (33), constructing the pyridine ring with advanced 
thiazole-containing building blocks 34−36. Using Bohlmann-Rahtz pyridine synthesis, various 
thiopeptide cores were obtained [134,154–159] (Scheme 11). In addition, a very early total synthesis of 
promothiocin A was achieved [125,160,161]. 
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Scheme 11. Synthesis of amythiamicins pyridine cluster using Bohlmann-Rahtz pyridine 
formation. Reagents and conditions: (a) 35, nBuLi; H2O, 91%; (b) TBAF, THF, rt, 1 h, 
93%; (c) NH4OAc, microwave, 120 °C (100 W), toluene, 30 min, 76%; (d) 36, EtOH,  
60 °C; toluene, AcOH, 70 °C, 85% (93% ee). SEM = 2-(trimethylsilyl)ethoxymethyl. 
 
The first synthesis of a polyheterocyclic core from the a (37) and b (38) series was reported by the 
group of Hashimoto. Their approach was based on formation of a substituted central 1-pyrroline 39 
that underwent ring-expansion to form a piperidine ring 37 (a series) that could be selectively oxidized 
for form the corresponding 2,3,4,5-tetrahydropyridine 38 (b series) [162] (Scheme 12). In further 
reports they described the synthesis of other fragments [163,164] of b series thiopeptides and finally 
achieved the total synthesis of siomycin A [165,166]. 
Scheme 12. Synthesis of a and b series central core by Hashimoto and co-workers. 
Reagents and conditions: (a) Et3N, THF, −25 °C, 71%; (b) TFA, EtOH; (c) NaBH3CN, 
AcOH, EtOH, 52% (2 steps); (d) Boc2O, DMAP, Et3N, THF, 0 °C, 84%;  
(e) (S)-Boc-Ala-OH, CIP, HOAt, DIPEA, CH2Cl2, 93%; (f) tBuOCl, THF, −78 °C, then 
cat. DMAP, Et3N, 95%. CIP = 2-chloro-1,3-dimethylimidazolidium hexafluorophosphates. 
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Cycloadditions have also been used for the synthesis of various central fragments. Almost 
simultaneously, the groups of Nicolaou [167] and Moody [132] developed two different bio-inspired 
strategies to obtain their target cores via an aza-Diels-Alder reaction. Nicolaou’s strategy was based on 
the silver-promoted formation of an aza-diene 40 from a precursor thiazolidine 41, which would 
dimerize in a [4 + 2] cycloaddition (Scheme 13). The 2,3,4,5-tetrahydropyridine 42 (b series) thus 
obtained after hydrolysis of the cycloaddition adduct could be oxidized to form the corresponding fully 
unsaturated d series core (43). 
Scheme 13. Bio-inspired synthesis of b and d series polyheterocyclic cores. Reagents and 
conditions: (a) Ag2CO3, BnNH2, DBU, pyridine, −15 °C, 1 h; then H2O/EtOAc (1:1), 1 h, 
60%; (b) DBU, EtOAc, reflux, 5 h, 50%. 
 
Using Nicolaou’s methodology various total syntheses were achieved, including the challenging 
thiostrepton [127,128,168], but also GE2270A and GE2270T [169], and various amythiamicins [170]. 
On the other hand, the strategy by Moody relied on a previously formed aza-diene 44, formed from the 
condensation of thiazoles 45 and 46 that could react with a different dienophile (47), yielding the 
aromatized cycloaddition product 48 [126,171] (Scheme 14). 
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Scheme 14. Bio-mimetic aza-Diels-Alder synthesis of 2,3,6-trisubstituted pyridine cores. 
Reagents and conditions: (a) Et3O
+
PF6
−
, CH2Cl2, 100%; (b) 46, CH2Cl2, then DBU, 
CHCl3, 63%; (c) 47, toluene, microwave, 120 °C, 33%. 
 
Alternatively, Arndt designed another aza-Diels-Alder strategy that was not based on the 
biosynthetic pathway, but used an alkyne 49 and a protected α,β-unsaturated oxime 50 as starting 
materials, giving access to 3-hydroxypyridines, such as 51. After a modified Hantzsch thiazole 
synthesis between 52 and 53, a precursor of the central core of nosiheptide (54) could be accessed [136] 
(Scheme 15). Using this strategy, the main macrocycle of nosiheptide could be synthesized [172]. 
Scheme 15. Synthesis of nosiheptide core via an aza-Diels-Alder cycloaddition. Reagents 
and conditions: (a) toluene, 180 °C, 55%; (b) Tf2O, Et3N, CH2Cl2, 0 °C; (c) TIPSOTf, 
Et3N, CH2Cl2,0 °C, 79% (2 steps); (d) NBS, THF/ H2O, 97%; (e) 53, KHCO3, THF,  
−40 °C; (f) TFAA, 2,6-lutidine, −20 °C, 60% (2 steps). 
 
Finally, one of the newest and most innovative contributions to the field is the synthesis of the 
central core of cyclothiazomycin hydrolysate 55 through a [2 + 2 + 2] ruthenium-catalyzed 
cyclotrimerization reaction between 56 and 57 [173] (Scheme 16). This yielded a product identical to 
that previously described by Bagley, thus confirming its identity [158]. 
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Scheme 16. Syntehsis of cyclothiazomycin central core hydrolysate via a [2 + 2 + 2] 
ruthenium-catalyzed cycloaddition. Reagents and conditions: (a) Cp*RuCl(COD),  
1,2-dichloroethane, 60 °C, 82%; (b) TBAF, THF, rt, 97%; (c) John’s reagent, acetone, 0 °C 
to rt; (d) TFA, CH2Cl2, rt, 80% (2 steps). Cp* = pentamethylcyclopentadienyl.  
TBAF = tetrabutylammonium fluoride. 
 
Future advances in the preparation of substituted pyridines will surely facilitate the total synthesis 
of thiopeptides that still pose a challenge, but most importantly, will give easy access to fragments and 
analogs for the development of thiopeptide-based drugs with an improved pharmacokinetic profile. 
2.6. In the Market 
To date, only two thiopeptides have hit the market, thiostrepton and nosiheptide. Although both are 
exclusively devoted to veterinary use, their applications are very different. The lack of thiopeptide 
formulations for human use stems from their low aqueous solubility, a limitation that also restricts 
their use in animals. 
Thiostrepton is used as one of the ingredients of an ointment for the treatment of cats and dogs skin 
infections. This ointment always has the same formulation (nystatin, 100,000 units; neomycin sulfate, 
2.5 mg; thiostrepton, 2500 units; triamcinolone acetonide, 1 mg) and is sold by different companies 
with a variety of brand names: Animax (Dechra), Resortin (Hannah), Panolog (Novartis), Dermalone 
(Vedco), etc. 
Alternatively, nosiheptide, is used as an animal growth promoter. This application was first 
described shortly after this thiopeptide was first isolated [174]. Nowadays, tons of pre-mixed animal 
food with the antibiotic are produced and commercialized. 
Given the bad pharmacokinetic profile of thiopeptides, various analogs have been produced, mainly 
to improve their aqueous solubility. LFF571 (Figure 1), developed by Novartis, is a semi-synthetic 
analog of GE2270A currently under clinical trials for the treatment of Clostridium difficile intestinal 
infections in humans [9,175,176]. 
When considering the great therapeutic potential of thiopeptides and the efforts carried out by many 
research groups, it can be expected that their discoveries will lead to the development of analogs 
suitable for the treatment of more threatening systemic infections. The discovery of new thiopeptides 
might also hold the key to the future development of these natural products into suitable drugs. 
Moreover, the still vastly unexplored oceans are likely to become a fruitful source of the new 
thiopeptides to come. 
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3. Summary 
A promising new family of antibacterial compounds, possessing other interesting bio-activities has 
been revised. Pioneering works from their isolation until the arrival to the marked though its 
biosynthesis, bio-activity and synthesis show that the thiopeptide are a wide range of investigation for 
scientists from different areas. 
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